Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2025-12-25 @ 9:22 PM
Study NCT ID:
NCT03473756
Status:
COMPLETED
Last Update Posted:
2025-04-09
First Post:
2018-03-16
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-05-15
Start Date Type:
ACTUAL
Primary Completion Date:
2021-07-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-07-10
Completion Date Type:
ACTUAL
First Submit Date:
2018-03-16
First Submit QC Date:
None
Study First Post Date:
2018-03-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-02-20
Results First Submit QC Date:
None
Results First Post Date:
2025-04-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-21
Last Update Post Date:
2025-04-09
Last Update Post Date Type:
ACTUAL